Rituximab is all the rage – and it should be – but it’s not the only immune modulating drug being tested in ME/CFS.
An immune modulating drug trial that recently opened in the Netherlands, of all places, could open new treatment possibilities as well. Because it will finish up before the Rituximab trial it could provide validation of this disease sooner as well.
It also suggests that attitudes are shifting in some surprising places.
Find out more about this encouraging drug trial in